Exosome-delivered NR2F1-AS1 and NR2F1 drive phenotypic transition from dormancy to proliferation in treatment-resistant prostate cancer via stabilizing hormonal receptors
Open Access
- 18 December 2024
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-18
Abstract
Cancer cells acquire the ability to reprogram their phenotype in response to targeted therapies, yet the transition from dormancy to proliferation in drug-resistant cancers remains poorly understood. In prostate cancer, we utilized high-plasticity mouse models and enzalutamide-resistant (ENZ-R) cellular models to elucidate NR2F1 as a key factor in lineage transition and ENZ resistance. Depletion of NR2F1 drives ENZ-R cells into a relative dormancy state, characterized by reduced proliferation and heightened drug resistance, while NR2F1 overexpression yields contrasting outcomes. Transcriptional sequencing analysis of NR2F1-silenced prostate cancer cells and tissues from the Cancer Genome Atlas-prostate cancer and SU2C cohorts indicated exosomes as the most enriched cell component, with pathways implicated in steroid hormone biosynthesis and drug metabolism. Moreover, NR2F1-AS1 forms a complex with SRSF1 to upregulate NR2F1 expression, facilitating its binding with ESR1 to sustain hormonal receptor expression and enhance proliferation in ENZ-R cells. Furthermore, HnRNPA2B1 interacts with NR2F1 and NR2F1-AS1, assisting their packaging into exosomes, wherein exosomal NR2F1 and NR2F1-AS1 promote the proliferation of dormant ENZ-R cells. Our works offer novel insights into the reawaking of dormant drug-resistant cancer cells governed by NR2F1 upregulation triggered by exosome-derived NR2F1-AS1 and NR2F1, suggesting therapeutic potential for phenotype reversal.Keywords
Funding Information
- National Natural Science Foundation of China (82203073, 82173039, 82103544)
- China Postdoctoral Science Foundation funded project (2022M711509)
This publication has 56 references indexed in Scilit:
- Mutant p53 activates hnRNPA2B1-AGAP1-mediated exosome formation to promote esophageal squamous cell carcinoma progressionCancer Letters, 2023
- FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancerCancer Cell, 2022
- Sangerbox: A comprehensive, interaction‐friendly clinical bioinformatics analysis platformiMeta, 2022
- ZEB1-regulated lnc-Nr2f1 promotes the migration and invasion of lung adenocarcinoma cellsCancer Letters, 2022
- Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin DysregulationCancer Cell, 2020
- Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implicationsCellular Oncology, 2019
- Hypoxia-Induced Resistance to Chemotherapy in Cancer2019
- Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular DormancyJournal of Cellular Biochemistry, 2016
- Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNACancer Cell, 2016
- Ineffectiveness of Doxorubicin Treatment on Solitary Dormant Mammary Carcinoma Cells or Late-developing MetastasesBreast Cancer Research and Treatment, 2003